Skip to main content
Follow-on offering raises $184M for MyoKardia
5/24/2018

A follow-on offering brought in $184 million for MyoKardia. The first patient in a late-stage Explorer-HCM study assessing its drug candidate mavacamten as a treatment of symptomatic, obstructive hypertrophic cardiomyopathy will be dosed this quarter.

Full Story: